BiotechTube

CX-2009 + CX-072

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasms

Conditions

Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative

Trial Timeline

Dec 29, 2020 → Jun 2, 2023

NCT ID
NCT04596150

About CX-2009 + CX-072

CX-2009 + CX-072 is a phase 2 stage product being developed by CytomX Therapeutics for Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT04596150. Target conditions include Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasms were approved

Approved (20) Terminated (2) Active (0)
✅LenvatinibEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved
✅Chlorhydrate de RopivacaineAstraZenecaApproved
✅Sitagliptin + placeboMerckApproved
✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04596150Phase 2Completed

Competing Products

20 competing products in Neoplasms

See all competitors
ProductCompanyStageHype Score
ADC-1013Alligator Bioscience ABPhase 1
19
AB0024Gilead SciencesPhase 1
29
TTI-237PfizerPhase 1
21
852APfizerPhase 1
29
PemetrexedEli LillyPhase 2
35
IMC-3C5Eli LillyPhase 1
29
LY3295668Eli LillyPhase 1/2
32
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
32
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
LY2784544Eli LillyPhase 1
29
enzastaurinEli LillyPhase 2
35
Abemaciclib + Darolutamide + LHRH agonist/antagonistEli LillyPhase 1
29
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
120 mg LY2784544Eli LillyPhase 2
39
LY4337713Eli LillyPhase 1
36
pemetrexed + cisplatinEli LillyPhase 1/2
32
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
47
VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mgVincerx PharmaPhase 1
19
VIP236 (Q3W) + VIP236 (Q2W)Vincerx PharmaPhase 1
19